Sarepta Therapeutics (SRPT) stock

Genetic medicines , market cap $1.9B

Genetic medicines

Worth $1.9B

$16.42

-4.76%

As of Tuesday's close · Live for Pro members at the open

Quality Score

-5

Poor

In its industry

#212of 281

Biotech

Checks firing

0of 14

Choppy

From 52-week high

-33.5%

under its best in a year

SRPT's Quality Score was unchanged on Tue, Nov 10, at -5.

Follow SRPT's trial news. Pro members can get an alert when Sarepta Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when SRPT files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEnd of 2026“Upcoming multiple ascending dose data from SRP-1003 in DM1 and SRP-1001 in FSHD expected by year end…”Trial data · SEC filing · Nov 5

Key facts on SRPT

Key facts on SRPT
Since its 2024 high	Down 89% while sales grew 57%
Latest filing	8-K, Nov 5 Reported its quarterly results

1 more reason behind SRPT's -5, free with an account →

SRPT in the news

TodayNo story names it yet.

What's next

Expected to report Wed Feb 24, after the close

After its last 4 reports it closed -2.7% on average, higher 2 of 4 times.

SRPT catalysts

Coming up

3 more coming up and 14 past catalysts since 2018, with sizes and sources, for Pro members.

What's next for SRPT

Next step the company has named

End of 2026“Upcoming multiple ascending dose data from SRP-1003 in DM1 and SRP-1001 in FSHD expected by year end; Company is actively preparing for Phase 3 development in both programs”Trial data · SEC filing · Nov 5

What it means: the first look at a trial’s main results, as the company reports them.

Lead program: SRP-1003 · Myotonic Dystrophy 1 · Phase 1/2
Its trial: SRP-1003 in Participants With Type 1 Myotonic DystrophyPhase 1/2 · By invitation · 78 people · main data estimated Dec 31, 2026 · NCT06138743

9 more trials, 3 more milestones and 26 filings, for Pro members.

Dilution on the horizon

Shelf registration (S-3ASR, filed Mar 3, 2025)
At-the-market share sales program (S-3ASR, filed Mar 3, 2025)

For Pro members: the amounts, and the share count against a year ago.

Insiders

Director Stephen Mayo sold 7,239 shares on Mar 12.

From Form 4: open-market buys and sales only.

Get an alert when Michael Severino buys or sells

For Pro members: every trade, and Michael Severino’s 4 filings and quotes.

Get an alert when SRPT files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why SRPT scores -5

Poorfor quality, not price, 0 of 14 chart checks firingWhat the Quality Score means

−3Long-term trend below a falling 200-⁠day average, down over one year, down over two years
−1Profit A loss of $115M over the last four quarters, less than the $142M lost a year earlier, from the SEC filingsRead on the last four quarters against the four before, or the last full year where no quarters are filed.

Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.

No effect today: Chart checks, Run-up, Size, Growth, Dilution, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on SRPT and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:29 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when SRPT's Quality Score turns up

A free account. No card.

How SRPT ranks in Biotech

SRPT is #212 of 281 by Quality Score.

How SRPT ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	SPROSpero Therapeutics		Open for its score
	SPRYARS Pharmaceuticals		Open for its score
	SRRKScholar Rock		Open for its score
	SRZNSurrozen		Open for its score
212	SRPTSarepta Therapeutics	0/14	-5

When does SRPT report earnings, and what happens after?

Expected to report Wed Feb 24, after the close (in 106 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What SRPT reported on Nov 5, 2026

The quarter

Sales of $381.4M, 5% less than a year ago; a loss of $0.27 a share.

“This primarily reflects a lower volume of ELEVIDYS sales due to the continued impact of our updated label that only includes the ambulatory patient population for treatment.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

Where the quarter's sales came from
Line	Q3 2026	Q2 2026	Q3 2025
By product
Pmo productsup 0.7%	$240M74%	$231M70%	$239M64%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)

1 more line, for Pro members.

The outlook

The outlook the company gave, by period
Measure	Figure
Full year 2026
Total net product revenue	$1.25B to $1.30Braised

Figures as filed (SEC filing, Nov 5)

1 more outlook line, for Pro members.

In the company's words

“Company expects ELEVIDYS net product revenue in the fourth quarter to trend in line with the third quarter, consistent with previous guidance and subject to normal variability associated with one-time gene therapy.”

From its results filing (SEC filing · Nov 5)

The numbers

Market value: $1.9B; today
Sales: $2B; down 18.9% on the year
Free cash flow: $176M; last 12 months

Sales grew 32% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 5.1% a year over 5 years.

5 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on SRPT: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-9.7%+5.3%+1.4%

May 6Aug 5Nov 5

Reported	When	Gap	Reaction	5 days
Nov 5, 2026After close	After close	+6.8%	+1.4%	not yet
Aug 5, 2026After close	After close	+4.6%	+5.3%	+15.4%
May 6, 2026After close	After close	-3.4%	-9.7%	-18.2%

SRPT closed higher after 2 of its last 4 reports.

All 4 reports, and SRPT's Quality Score going into each

SRPT sales and profit by year

Sales and profit by year

Sales grew every year from 2018 to 2025, to $2.2B. It lost money in 2025 after a profit in 2024.

Nothing is firing on SRPT right now

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on SRPT, and all 14 on every stock.Get in free →

SRPT RSI today: 38.2, below its 50-day and 200-day averages

Not scored

RSI 38.2, MACD below signal, below both averages. Not scored.13 readings

The deep dive on SRPT

What it does and how it makes money3 findings"In addition, the Roche Collaboration Agreement provides that Roche will pay us royalties on net sales of ELEVIDYS, at a tiered royalty rate based on the average cost to manufacture ELEVIDYS." (10-K for fiscal 2025)SEC filing · Mar 2, 2026
Where it stands2 findingsFor Pro members2 findings on where SRPT stands: its cash, debt, and share count, for Pro members
What changed in its filings7 findings"On September 15, 2026, the court granted Sarepta and the named defendants' motion to dismiss and dismissed the case with prejudice." (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 5, 2026A new heading in its "Risk Factors" this year: "Interim, initial, “topline” and preliminary data from our clinical trials that we announce or publish from time to time are subject to audit and verification procedures and may differ materially from final data as more patient data become available." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Mar 2, 2026, against the one of Feb 28, 2025One customer made up 27% of its revenue in fiscal 2025, down from 31% in fiscal 2024.SEC filing · Mar 2, 2026
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades SRPT, for Pro members

11 more findings on SRPT, each with its source, for Pro members.

SRPT share count over time

Shares: 5.7% more than a year ago (to Sep 30).

Shares of SRPT outstanding, as filed
Shares outstanding	As of
107.2M	Nov 2, 2026
105.6M	Jul 31, 2026
105.6M	May 1, 2026
105M	Feb 24, 2026

Offerings, shelves, and splits of SRPT, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Mar 3, 2025

SRPT insider trades

SRPT trades by Congress and the executive branch

2 trades disclosed in the last six months. The newest:

SellDonald Trump$15K to $50KPresident (R)traded Jul 29, disclosed Sep 22(55 days later)

SellDonald TrumpPresident (R)$15K to $50Ktraded Jul 29, disclosed Sep 22(55 days later)

All 2 trades on SRPT disclosed by Congress and the executive branch, for Pro members.Get in free →

See what Congress is buying across the market

SRPT's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Douglas S. IngramChief Executive Officer · no trades on file
Michael SeverinoChief Executive Officer · no trades on file
Ryan Ho-Yan WongChief Financial Officer · no trades on file
Ian Michael EstepanChief Operating Officer · 1 trade
Cristin RothfussEVP, General Counsel · no trades on file
Louise Rodino-KlapacPresident, R&D and Tech Ops · no trades on file
Stephen MayoDirector · 1 trade
Claude NicaiseDirector · no trades on file

6 more officers and directors file at SRPT.

See insider trades by person

Which ETFs hold SRPT?

In ETFs: SRPT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Sarepta Therapeutics

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

835 employeesCambridge, MAsarepta.com

What Sarepta Therapeutics says it competes with

“The pharmaceutical and biotechnology industries are intensely competitive, and any product or product candidate developed by us competes or would likely compete with existing drugs and therapies.”

From its annual report, SEC filing · Mar 2, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on SRPT and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn SRPT's score around: 7 things
4 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawaySep 22Donald Trump sold SRPT$15K to $50K, disclosed Sep 22

Alerts are optional.

See SRPT's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: SRPT's Quality Score is -5 (Poor), #212 of 281 in Biotech.

What does SRPT's Quality Score say?

SRPT scores -5 today, which Breakaway calls Poor. It is #212 of 281 in Biotech by Quality Score, with 0 of 14 chart checks firing. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is SRPT's Quality Score?

SRPT scores -5 today, which Breakaway calls Poor (below zero). That is #212 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind SRPT's -5.

When does SRPT report earnings?

Expected to report Wed Feb 24, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. SRPT closed higher after 2 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.